Investor Relations

Investor Relations

BrainsWay is an industry leader in the field of transcranial magnetic stimulation (TMS).  BrainsWay’s flagship Deep TMS technology is a non-invasive, well-tolerated outpatient treatment, clinically proven to treat psychiatric and neurological conditions. 

BrainsWay has received FDA-clearance for both major depression (MDD) and obsessive compulsive disorder (OCD- De Novo) and is developing more applications outside of the US.  The company also has approval in Canada, Japan and other Asian countries. BrainsWay continues to push the TMS envelope with multiple clinical studies and further research into novel indications.

BrainsWay has an experienced business and development management team, as well as the backing of key scientific opinion leaders.

BrainsWay was founded in 2003 and began trading on the NASDAQ in 2019 under the symbol BWAY.

Latest releases
June 17, 2019
Brainsway Announces Changes to its Board of Directors
Professor Abraham Zangen, Ph.D. Appointed as a Director JERUSALEM, Israel and HACKENSACK, N.J., June 17, 2019 (GLOBE NEWSWIRE) -- Brainsway Ltd. (NASDAQ & TASE: BWAY) (Brainsway), a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products

Questions for the Investor Relations Department can be submitted through the form below.

Fields marked with an * are required.

For more information please contact:

Mr. Hadar Levy, CFO

Office Tel +972-2-647-6010

Mobile +972-54-5699133

Fax +972-2-581-2517

US: +1-844-386-7001  or 1-844-DTMS-001

Email hadarl@brainsway.com

Copyright West LLC. Minimum 15 minutes delayed.